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Proinﬂammatory cytokines, such as tumour necrosis factor α (TNFα), play fundamental roles in the pathogenesis of acute
pancreatitis (AP). The aim of this study was to determine if polymorphisms in the TNFα gene are associated with AP. Two
polymorphismslocatedinthepromoterregion(positions −308and −238)inTNFαgeneweredeterminedusingpolymerasechain
reaction- (PCR-) restriction fragment length polymorphism (RFLP) methods in 103 patients with AP and 92 healthy controls.
Odds ratios (ORs) and 95% conﬁdence intervals (CI) were estimated using logistic regression analysis adjusted for age, sex, BMI
and smoking. The frequencies of TNFα polymorphisms were both similar in patients with mild or severe pancreatitis, so were in
pancreatitis patients and in controls. We suggest that both SNPs of TNFα are not genetic risk factor for AP susceptibility (OR =
1.63; 95% CI: 1.13−4.01 for TNFα−308 and OR = 0.86; 95% CI: 0.75−1.77 for TNFα−238).
1.Introduction
AP is a common disease whose severity varies widely
from mild forms only aﬀecting the pancreas (80% of the
patients) to severe forms associated with multiple organ
failure (20% of the patients). The reported incidence is
approximately 30–40 per 100000 population per year and
25% will develop severe or life threatening complications
[1, 2]. The mechanisms responsible for the development of
pancreatitis have not yet been fully elucidated. However, it
has been clearly known that one of the important factors,
activating pancreatic stellate cells during pancreatic injury, is
proinﬂammatorycytokinesknowntobeupregulatedearlyin
the course of acute pancreatic inﬂammation [3, 4]. Genetic
factors, especially related to cytokines, may play important
roles in susceptibility to pancreatic injury, as well as in
the severity and evolution of the inﬂammatory process
[5].
Tumour necrosis factor α (TNFα), thought to be the
ﬁrst cytokine released, is a principal mediator of immune
responses [6]. The gene that codiﬁes for TNFα is located
within the major histocompatibility complex (MHC) class
III region in the short arm of the human sixth chromosome
[7]. Two biallelic polymorphisms in the promoter region of
the TNFα gene may be relevant for the production of TNF
[8]. The ﬁrst one at the position −238 nucleotides relative to
the transcriptional start site lies within a putative regulator
sequence where a G to A substitution deﬁnes two variants
(TNFα−238 Ga n dT N F α−238 A). The second polymorphism
at position −308 is also a point mutation, where the presence
of G deﬁnes the common variant TNFα−308 G and A deﬁnes
the less common variant TNFα−308 A[ 9]. Although some
researches have showen that SNPs of TNFα are associated
with inﬂammatory diseases in pancreas, identiﬁcation of
an association between the polymorphisms of TNFα and
susceptibility to AP is less clear [10–13]. In the present study,
our aim was to determine the association between TNFα
promoter polymorphism (TNFα−308;T N F α−238)a n dA P
susceptibility in patients with AP and controls nested within
the Hospital of Istanbul University, Turkey. We hypothesized
these polymorphisms could inﬂuence the risk of AP. This
article can be signiﬁcant for the approach to the possible
relationshipbetweenkeyinﬂammatorygenepolymorphisms
and pancreatitis.2 Mediators of Inﬂammation
2.MaterialandMethods
2.1. Study Population. Blood samples were collected from
103 patients with AP seen at the Emergency Service, the
Hospital of Istanbul University, Turkey between March 2008
and March 2009. The criteria for diagnosis of AP were:
a clinical history consistent with the disease, appropriate
radiological evidence, and serum amylase level greater
than 3 times the upper limit of normal. The progress of
individuals with regard to development of complications
was monitored during their disease episode. The disease
severity was classiﬁed as mild or severe according to criteria
deﬁned by the Atlanta Consensus Conference [14]. Cases
consisted of 68 patients with mild and 35 patients with
severe AP. As a control group, 92 healthy ethnically matched
subjects were obtained during the same period to examine
association between TNFα genotypes and susceptibility to
pancreatitis.Thecontrolsshowednoevidenceofpancreatitis
or cancer. Ethical approval for the study was obtained
from the Local Research Ethics Committee, Istanbul, Turkey.
All participants provided written informed consent. We
recorded the smoking status in addition to age, BMI, sex
and family history. For smoking status, a person who had
smoked at least once a day for >1 year in his or her lifetime
was regarded as a smoker.
2.2. Selection of Single Nucleotide Polymorphisms. The
human TNFα gene situated on the short arm of chromo-
some 6 at p21.3 locus [7]. We collected data on TNFα
polymorphisms from publicly available databases, such as
dbSNP (http://www.ncbi.nlm.nih.gov/) and HapMap Phase
II database (http://hapmap.org/index.html.en). The studied
SNPs (TNFα−308 (rs1800629) and TNFα−238 (rs361525))
were chosen according to the following criteria: (a) minor
allele frequency of 5% or greater in Caucasians, according to
literature data, (b) previous epidemiologic ﬁndings indicat-
ing associations with pancreatitis and cancer susceptibility.
2.3. Genotyping. Genomic DNA was extracted from blood
samples using a sodium perchlorate/chloroform extraction
as described by Daly et al. [15]. Genotypes of TNFα
polymorphisms were determined by PCR-RFLP methods.
Genotyping was performed without knowledge of sub-
jects’ patients or control status. The sequences of primers
were designed by GenBank (accession numbers; NT007592;
NM000594).ForPCRampliﬁcation,genomicDNA(100ng–
1μg) was added to 25μL of PCR master-mix as described
by Daly et al. [15]. The PCR products were digested with
the various restriction enzymes. Digestion products were
analysed by electrophoresis on 10% polyacrylamide gels
with TBE buﬀer. Band patterns representing the various
genotypes are summarized in below.
For TNFα−308 G > A (rs1800629), primers were 5 -
ATCTGGAGGAAGCGGTAGTG-3  and 5 -AATAGGTTT-
TGAGGGCCATG-3 . The following PCR protocol was used:
94◦Cf o r3m i n u t e s ;3 5c y c l e so f9 4 ◦C for 30 seconds, 55◦C
for 30 seconds, 72◦C for 30 seconds; 72◦Cf o r5m i n u t e s .T h e
PCR product was directly digested with 2 U NcoI restriction
enzyme at 37◦C for overnight. Digestion with NcoIp r o d u c e d
an uncut 222-bp fragment from the mutant allele (TNFα−308
A), 130- and 20-bp fragments from the wild-type allele
(TNFα−308 G).
For TNFα−238 G > A (rs361525), primers were 5 -ATC-
TGGAGGAAGCGGTAGTG-3  and 5 -AGAAGACCCCCC-
TCGGAACC-3 . The following PCR protocol was used:
94◦Cf o r3m i n u t e s ;3 5c y c l e so f9 4 ◦C for 30 seconds, 57◦C
for 30 seconds, 72◦C for 30 seconds; 72◦Cf o r5m i n u t e s .
The PCR product was directly digested with 2 U MspI
restriction enzyme at 37◦C for overnight. Digestion with
MspI produced an uncut 150-bp fragment from the mutant
allele (TNFα−238 A), 130- and 20-bp fragments from the
wild-type allele (TNFα−238 G).
To assess reliability of genotyping, analysis repeated on
10% of the samples.
2.4. Statistical Analysis. Statistical analysis was conducted by
using the computer software Statistical Package for Social
Sciences-SPSS for windows (version 13.0) (Chicago, IL).
ORs and 95% CIs were estimated by conditional logistic
regression analyses based on the comparison of genotypes
between patients with AP and healthy controls, adjusting
for the potential confounders, age, BMI, sex, smoking.
Hardy-Weinberg equilibrium was tested to compare the
observed and expected genotype frequencies among cases
and controls, respectively. A two-sided P-value <.05 was
considered to be statistically signiﬁcant. For analyses of
genotype frequencies, the wild-type category (chosen either
as the most common wild-type frequency or arbitrarily if
both alleles showed similar frequencies) was the reference
group.
3. Results
There were no signiﬁcant diﬀerences between the cases and
controls for the mean age and sex distribution, and this
suggested that the matching based on these two variables
was adequate. The mean age (±SD) was 52.7 (±15.1) years
for patients and 46.7 (±16.4) years for controls (P = .729).
In this study, a signiﬁcant association was observed for
interaction between BMI and AP risk (OR = 3.07; 95%
CI: 1.68−5.60; P = .0002) (Table 1). As it can be seen in
Table 2, no association between TNFα genotypes and family
history of pancreatitis or any cancer was detected in our
study. Firstly, we tested the association between two TNFα
SNPs (TNFα−308,T N F α−238) and AP risk in our study of
103 cases and 92 controls. TNFα−308 Aa n dT N F α−238G,
the highest allele frequencies observed in our study, were
0.616 and 0.870 in cases compared with 0.587 and 0.891 in
controls, respectively. The observed genotype frequencies of
allsevenSNPsincasesandcontrolsconformedtotheHardy-
Weinberg equilibrium. We then analyzed the diﬀerences
between cases and controls in the distribution of genotype.
Genotype distribution of two SNPs (rs1800629; rs361525)
in cases and controls did not signiﬁcantly diﬀer (P>. 05)
and thus these polymorphisms were not associated with
risk of pancreatic cancer (Table 2). Similarly, there wasMediators of Inﬂammation 3
Table 1: Distribution of select characteristics among AP patients and controls.
Cases (%) n = 103 Control (%) n = 92 OR (95% CI) P-value
Gender
Male 55 (53.4) 45 (48.9) 1.00 (reference) .532
Female 48 (46.6) 47 (51.1) 1.2 (0.68−2.10)
Age
≤60 30 (29.1) 25 (27.2) 1.00 (reference) .729
>60 72 (69.9) 67 (72.8) 0.90 (0.48−1.68)
Missing 1 (1.0) —
Family history
No 80 (77.7) 82 (89.1) 1.00 (reference) .150
Yes 18 (17.5) 10 (10.9) 1.85 (0.80−4.24)
Missing 5 (4.9)
BMI∗
≤25 48 (46.6) 25 (27.2) 1.00 (reference) .0002
>25 55 (53.4) 67 (72.8) 3.07 (1.68−5.60)
Smoking status
Non-smoking 57 (55.3) 63 (68.5) 1.00 (reference)
Smoking 46 (44.7) 30 (32.6) 1.70 (0.95−3.04) .075
∗BMI; body mass index (kg/m2).
Table 2: Genotype frequencies of TNFα among cases and controls and the association with AP risk. ORs with 95% CI and P-values were
calculated for wild/wild genotype versus wild/mutant and mutant/mutant genotypes.
TNFα polymorphisms Genotype Cases (%) n = 103 Controls (%) n = 92 OR (95% CI)∗ P-value
TNFα−308 G > A rs1800629
GG 15 (14.6) 21 (22.8) GG versus any A .145
GA 43 (41.8) 34 (37.0) 1.63 (1.13−4.01)
AA 45 (43.7) 37 (40.2)
TNFα−238 G > A rs361525
GG 90 (87.4) 73 (79.4) GG versus any A .175
GA 8 (7.8) 18 (19.6) 0.86 (0.75−1.77)
AA 5 (4.9) 1 (1.1)
∗OR: odds ratio; CI: 95% conﬁdence interval; OR adjusted for age, sex, BMI, smoking status for logistic regression analysis.
no signiﬁcant diﬀerence in the distribution of two TNFα
gene polymorphisms studied between patients with mild
or severe diseases. Finally, we investigated the associations
between smoking status both AP risk and the two TNFα
polymorphisms. Smoking was slightly associated with the
risk of AP (OR = 1.70; 95% CI: 0.95−3.04; P = .075) while
it was no observation any association between smoking and
the studied polymorphisms (P = .1).
4. Discussion
The link between inﬂammation and the development of
cancer has been recognized by a number of researchers since
Rudolf Virchow noted leukocytes in neoplastic tissue and
suggested that there was a connection between cancer and
inﬂammation in 1863 [16, 17]. Although many forms of
pancreatitis have been linked to a higher risk for pancreatic
cancer, the relationship between the two is ill-deﬁned [18,
19]. The course of chronic pancreatitis is characterized by
recurrent episodes of AP, which cause parenchymal injury
and necrosis, with increasing amounts of ﬁbrosis, chronic
inﬂammation,andparenchymalcelllosswitheachsuccessive
episode [20, 21]. Patients with chronic pancreatitis have an
increased risk of developing pancreatic cancer with a rate
15- to 16-fold greater than that of the general population
[20]. It can be seen that AP is ﬁrst step in this pathway
progressed from inﬂammation to cancer in pancreas. How-
ever, inﬂammation alone usually does not lead to cancer.
Several factors have been implicated for the recent rise in
the frequency of AP, including age, alcohol consumption,
smoking, gallstones, diet high in animal fat, and genetic
disorders [21, 22]. On the contrary to the results obtained
from some researches [23, 24]. No association between the
risk of AP and family history was detected in this study
(Table 1). It is indicated that smoking status, duration and
intensity were risk factors for AP by the researchers [25–27].
Wefoundthattherewasaweakassociationbetweencigarette
smoking and development of AP in the study population
(OR = 1.59; 95% CI: 0.89−2.84; P = .075) (Table 1).
Further investigation with more samples would be better to
determine strictly this association. As to BMI, a signiﬁcant
association was observed for interaction between BMI and
AP risk (OR = 3.07; 95% CI: 1.68−5.60; P = .0002) similar4 Mediators of Inﬂammation
to the results obtained from Lindkvist et al. [28] and Gumbs
[29]. However, there was no speciﬁcally interaction between
any studied polymorphisms and BMI. In two SNPs, the risk
of AP was higher than <2-fold from the point of view of
BMI (no data shown). The main limitation of our study is
the relative small study size, which may result in less precise
estimation of gene-environment interaction in AP.
TNFα expression in the pancreas is increased by the
onset of experimental pancreatitis, and antagonism of TNFα
reduces the severity of local pancreatic inﬂammation. Levels
of soluble TNFα receptors, indicators of TNFα activity,
have been found to be increased in patients with severe
disease, and TNFα blockade has been shown to reduce
mortality and ameliorate markers of severe systemic disease
in experimental AP [30–34]. TNFα polymorphisms have
been associated with susceptibility and outcome of various
infectious, inﬂammatory and neoplastic diseases [35–37].
As to AP, identiﬁcation of an association between the
polymorphisms of TNFα and susceptibility to AP is less
clear, although several SNPs in TNFα have been reported
previouslyinbothmanyformsofpancreatitisandpancreatic
cancer. A signiﬁcant association between TNFα at position
−308 and −238 has recently been described in patients
with chronic pancreatitis and with pancreatic cancer [13, 14,
38, 39] while some researches have reported no association
between TNFα polymorphism and susceptibility chronic
pancreatitis or pancreatic cancer [40–42]. Beranek et al. [43]
found that TNFα−238 might be a relevant risk factor for
diseasemanifestationinfamilieswithhereditarypancreatitis.
On the contrary, there was no association between TNFα−238
polymorphism and the risk of AP (OR = 0.86; 95% CI:
0.75−1.77; P = .175) in the study (Table 2). Balog et al.
[12] obtained that TNFα−308 A alleles were associated with
risk of AP. They noticed that genotype assessments may be
important prognostic tools to predict disease severity and
the course of AP. However, Zhang et al. [44] found no
associationbetweenAPandTNFα−308 inChinesepopulation
withAP.But,theysuggestthatTNFα−308 Aalleleisassociated
with a susceptibility to severe sepsis complicating of AP.
TNFα−308was genotyped in AP patients in UK population
by Sargen et al. [45]a n dP o w e l le ta l .[ 46]. They found that
TNFα−308 plays no part in determination of disease severity
or susceptibility to AP. Similarly, we found there was no
association between TNFα−308 polymorphism and the risk
of AP (OR = 1.63; 95% CI: 1.13−4.01; P = .145) (Table 2).
We have also observed that the TNFα gene polymorphisms
studied were not associated with disease severity in AP (no
data shown).
In conclusion, we obtained the results on the contrary
to our hypothesis. It is unlikely that the studied SNPs
(TNFα−308 and TNFα−238)w i l lr e g u l a t eA P .I nc o m p l e x
biologic disease processes such as AP, the eﬀect of an
SNP in inﬂammation process may be minimized through
the interaction of other factors. Also, there are several
potential reasons for failing to observe any association
between TNFα gene polymorphisms studied and levels of
disease severity. It is, perhaps, therefore not surprising that
single gene polymorphisms do not correlate with outcome
in patients with mild or severe AP. Therefore, additional
studies on a larger group of patients will be required to
conﬁrm these ﬁndings. Besides, further studies on the level
of expression of TNFα gene and on the other potential
SNPs in neighbouring genes and in other inﬂammatory
cytokines may likely provide additional insight into the role
and implications of alterations in individual susceptibility
to AP. We believe that any clariﬁcation of mechanisms
linking inﬂammation and cancers will be beneﬁcial to the
development of eﬃcacious prevention and therapies of
inﬂammation-associated cancers.
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